BRIEF published on 08/27/2024 at 13:05, 1 year 10 months ago Pharnext begins liquidation proceedings Creditors Liquidation Paris Commercial Court Pharnext Suspension Of Listing
BRIEF published on 08/27/2024 at 13:05, 1 year 10 months ago Pharnext entame une procédure de liquidation judiciaire Liquidation Judiciaire Tribunal De Commerce De Paris Suspension De Cotation Pharnext Créditeurs
PRESS RELEASE published on 08/27/2024 at 13:00, 1 year 10 months ago Ouverture d'une procédure de liquidation judiciaire Pharnext SCA, société biopharmaceutique en liquidation judiciaire après procédure de conciliation. Suspension de la cotation des actions Biopharmaceutique Liquidation Judiciaire Suspension Cotation Pharnext Procédure Conciliation
BRIEF published on 07/04/2024 at 20:05, 2 years ago Pharnext announces the termination of the financing contract granted by Néovacs Investors Termination Funding Pharnext Néovacs
BRIEF published on 07/04/2024 at 20:05, 2 years ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Financement Investisseurs Pharnext Résiliation Néovacs
PRESS RELEASE published on 07/04/2024 at 20:00, 2 years ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Pharnext annonce la résiliation anticipée du contrat de financement avec Néovacs suite à des cas de défaut. La société sollicite Global Tech Opportunities 13 pour son soutien Financement Pharnext Résiliation Néovacs Global Tech Opportunities
BRIEF published on 06/18/2024 at 18:35, 2 years 1 month ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext Procédure De Conciliation CMT1A PXT3003 Tasly
BRIEF published on 06/18/2024 at 18:35, 2 years 1 month ago Pharnext announces the extension of the conciliation procedure until July 15, 2024 Pharnext Conciliation Procedure CMT1A PXT3003 Tasly
PRESS RELEASE published on 06/18/2024 at 18:30, 2 years 1 month ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 pour poursuivre l'étude clinique de Phase III de PXT3003. Les résultats seront communiqués prochainement Conciliation Étude Clinique Pharnext PXT3003 Maladie Neurodégénérative
BRIEF published on 05/07/2024 at 19:15, 2 years 2 months ago Adjustment of the nominal value at Pharnext Biopharmaceutical Capital Reduction Pharnext Nominal Value Neurodegenerative Diseases
Published on 07/22/2026 at 03:10, 35 minutes ago High Tide Resources Corp. Announces Change of Auditor
Published on 07/22/2026 at 02:30, 1 hour 15 minutes ago Avidian Gold Corp. Announces Change of Auditor
Published on 07/21/2026 at 23:00, 4 hours 45 minutes ago Viemed Healthcare Announces Second Quarter 2026 Earnings Conference Call Details
Published on 07/21/2026 at 22:30, 5 hours 15 minutes ago Fermi Announces First Siemens Turbines Arrive at Port of Houston
Published on 07/21/2026 at 22:30, 5 hours 15 minutes ago Matador Technologies Announces Management Transition
Published on 07/22/2026 at 01:05, 2 hours 40 minutes ago Quantinuum and SoftBank Corp. Publish Joint White Paper on Scaling Practical Quantum Computing Use Cases Toward the Fault-Tolerant Era
Published on 07/21/2026 at 22:30, 5 hours 15 minutes ago Strong second quarter: GEA raises full-year guidance for 2026
Published on 07/21/2026 at 22:16, 5 hours 28 minutes ago EQS-Adhoc: GEA Group Aktiengesellschaft: Preliminary numbers for Q2 2026 exceed market expectation - increase of guidance for fiscal year 2026
Published on 07/21/2026 at 18:50, 8 hours 55 minutes ago Soapeya, a DN Group AG Portfolio Company, Earns Top "Excellent" Rating from Dermatest and Proves Successful in Field Use in Ghana
Published on 07/21/2026 at 18:15, 9 hours 29 minutes ago EuroTeleSites Reports Strong Q2/2026 Results with Growth Across Key Financial and Operating Metrics
